Abstract
Atopic dermatitis (AD) is a chronic, relapsing, inflammatory systemic condition. Recently, dupilumab has been reimbursed by Italian Medicines Agency (AIFA) for the treatment of adolescents (according to the AIFA registry criteria) and adults with severe AD. Furthermore, it has been authorized by European Medicines Agency in children with severe AD. The objective of this analysis was to estimate the incremental cost-effectiveness ratio (ICER) of dupilumab versus current supportive care (SC), for the treatment of severe AD in children (6-11 years) and adolescents (12-17 years) in Italy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
